Ashland (ASH) Up 2% Since Last Earnings Report: Can It Continue?
Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
$1.67 per share
Est. EPS $3.53 · Revenue $1.86B · 6 analysts
Est. EPS $0.36 · Revenue $404.35M · 3 analysts
Est. EPS $1.20 · Revenue $504.88M · 1 analysts
$1.67 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.8B | -13.7% | +3.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-845.0M | -600.0% | 0.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +30.1% | +2.9% | +2.3% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -42.5% | -3353.1% | +2.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -46.3% | -679.2% | -3.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-4.0M | -101.5% | +325.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -0.2% | -101.7% | +312.2% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 82.7% | +61.6% | -0.3% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.85x | +16.8% | -0.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $4.6B | -18.3% | +1.8% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -18.37 vs 3.55 | -617.0% | 0.35 vs 0.98 | -64.5% |
| Revenue Surprise | $1.8B vs $1.8B | -0.2% | $497.0M vs $486.0M | +2.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | LAMPKIN ROBIN E. | officer: SVP, GC & Secretary | Common Stock | A | 1,806 | $74.58 |
| Aug 11, 2026 | LAMPKIN ROBIN E. | officer: SVP, GC & Secretary | Common Stock | D | 526 | $74.58 |
| Aug 11, 2026 | LAMPKIN ROBIN E. | officer: SVP, GC & Secretary | Restricted Stock Unit | A | 1,806 | — |
| Jul 29, 2026 | MUSA OSAMA M | officer: SVP and CTO | Common Stock | A | 1,267 | $57.96 |
| Jul 29, 2026 | MUSA OSAMA M | officer: SVP and CTO | Stock Appreciation Rights | D | 9,793 | $57.96 |
Operator: Good day, and thank you for standing by. Welcome to the Ashland Third Quarter Conference Earnings Call. At this time, all participants are in a listen-only mode. To ask a question during the session, you will need to press *11 on your telephone. You will hear an automated message advising that your hand is raised. To withdraw your question, please press *11 again. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your first speaker today, Sandy Klugman, Director of Investor Relations. Sandy Klugman: Thank you, Sandy. Thank you. Hello, everyone, and welcome to Ashland's third quarter fiscal year 26 Earnings Conference Call and Webcast. My name is Sandy Klugman, and I am Ashland's Director of Investor Relations. Joining me on the call today are Guillermo Novo, Chairman and CEO; William Whittaker, CFO; as well as our business unit leaders. Alessandra Faccin, life sciences and Intermediates; James Minicucci, Personal Care; and Dago Caceres, Specialty Additives. Please note that we will be referencing slides during today's call. We encourage you to follow along with webcast materials available at ashland.com under Investor Relations. Please turn to Slide 2. As a reminder, today's presentation contains forward looking statements regarding our fiscal 26 outlook, and other matters as detailed on Slide 2, And in our Form 10 Q. These statements are subject to risks and uncertainties that could cause future results to differ materially from today's projections. We believe any such statements are based on reasonable assumptions, but there is no assurance these expectations will be achieved. We will also reference certain adjusted financial metrics. Both actual and projected, which are non GAAP measures. Present these adjusted figures to provide additional insight into our ongoing business performance. GAAP reconciliations are available on our website and in the appendix of these slides. Guillermo Novo: I will now hand the call over to Guillermo for his opening remarks. Thanks, Sandy, and welcome to everyone joining us. Please turn to slide 5. Overall, we delivered a strong third quarter that reflected strong demand, disciplined commercial execution and healthy free cash flow generation. James increased across all business units and our performance was in line with the expectations we outlined at the beginning of the quarter. These results reflect the team's strong execution and reinforce the momentum we are building across the businesses. Life Sciences delivered double digit sales growth, benefiting from broad contributions across pharma end markets and ongoing momentum within our Globalize and Innovate strategies. Pharma achieved its 5th consecutive quarter of volume growth supported by strength in high purity excipients, injectables, and innovation growth momentum. Personal care generated another quarter of solid performance. Led by biofunctionals actives, high single digits growth …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Guillermo Novo | Chairman & Chief Executive Officer | USD 2,673,560 | Male | 1962 | Active |
Alessandra Faccin | Senior Vice President and GM of Life Sciences & Intermediates | USD 1,309,381 | Female | 1980 | Active |
Wayne Muil | Senior Vice President of Operations | USD 1,119,511 | Male | — | Active |
Osama Musa | Senior Vice President & Chief Technology Officer | USD 936,184 | — | 1968 | Active |
James Minicucci | Senior Vice President & GM of Personal Care | USD 829,662 | Male | 1982 | Active |
William C. Whitaker | Senior Vice President, Chief Financial Officer & Director of Investor Relations | USD 601,710 | Male | 1989 | Active |
Eileen Drury | Senior Vice President & Chief HR Officer | — | Female | 1968 | Active |
Robin E. Lampkin | Senior Vice President, General Counsel & Secretary | — | Female | 1963 | Active |
Carolmarie C. Brown | Vice President of Corporate Affairs, Global Marketing, Brand & Business Communications | — | — | — | Active |
Samuel A. Richardson | VP, Controller & Principal Accounting Officer | — | Male | 1979 | Active |
Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

Ashland launches Permexa sodium caprate to support oral peptide and biologic development with enhanced processing and permeability.

Deutsche Bank AG purchased a new stake in Ashland Inc. (NYSE: ASH) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 83,987 shares of the basic materials company's stock, valued at approximately $5,534,000. Deutsche Bank AG owned 0.18% of Ashland

WILMINGTON, Del., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH), is announcing the launch of permexa™ sodium caprate, a high-performance intestinal permeation enhancer designed to support the scalable development and commercialization of oral peptide, biologic and low-permeability drug products, including rapidly expanding GLP-1 agonists and related therapeutic pipelines.

Bank of America Corp DE cut its holdings in shares of Ashland Inc. (NYSE: ASH) by 4.9% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 445,596 shares of the basic materials company's stock after selling 22,944 shares during the period. Bank of America
